New long-term data from two clinical trials of a gene therapy for Leber hereditary optic neuropathy (LHON) have shown that the treatment can lead to clinically meaningful improvements in visual function, researchers reported at NANOS 2020.
New long-term data from two clinical trials of a gene therapy for Leber hereditary optic neuropathy (LHON) have shown that the treatment can lead to clinically meaningful improvements in visual function, researchers reported at NANOS 2020.